Label Changes for:
EC-Naprosyn (naproxen delayed-release tablets)
Changes have been made to the WARNINGS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
- Patients at greatest risk of this reaction are those taking………..or angiotensin receptor blockers (ARBs),
Advanced Renal Disease
- ...and patients should be adequately hydrated.